Luminist Labs
Diagnostic platform for early detection of liver disease
Medical Devices
Diagnostics
Genomics
About
Luminist developed a non-invasive diagnostic test for the early detection and staging of liver fibrosis and non-alcoholic steatohepatitis (NASH). Luminist was acquired in 2020 by DiscernDx.
Build your own investing agent
GPAgent keeps YC listings public and neutral. Fund-specific scoring, notes, and workflow state live in each customer workspace.
Join the GPAgent waitlistDetails
Status
Acquired
Stage
Early
Team Size
2
Regions
United States of America, America / Canada